New Data Position Lazertinib As Strong Contender In 1L NSCLC
Potential Tagrisso Challenger?
Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.
